Oxidized LDL Antibodies in Treatment and Risk Assessment of Atherosclerosis and Associated Cardiovascular Disease

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|13|10|1021-1030

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.13, Iss.10, 2007-04, pp. : 1021-1030

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oxidized LDL, LOX-1 and Atherosclerosis

By Mitra Sona  

Cardiovascular Drugs and Therapy, Vol. 25, Iss. 5, 2011-10 ,pp. : 419-429

Springer Publishing Company

Access to resources Recommend Favorite

Cardiovascular Disease and Dyslipidemia: Beyond LDL

By  

Current Pharmaceutical Design, Vol. 17, Iss. 9, 2011-03 ,pp. : 861-870

Bentham Science Publishers

Access to resources Recommend Favorite

Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease

By  

Current Pharmaceutical Design, Vol. 18, Iss. 33, 2012-11 ,pp. : 5362-5378

Bentham Science Publishers

Access to resources Recommend Favorite

Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures

By  

Current Pharmaceutical Design, Vol. 9, Iss. 29, 2003-11 ,pp. : 2417-2423

Bentham Science Publishers

Access to resources Recommend Favorite

Regression or Reduction in Progression of Atherosclerosis, and Avoidance of Coronary Events, With Lovastatin in Patients With or at High Risk of Cardiovascular Disease: A Review

By Frisinghelli Anna  

Clinical Drug Investigation, Vol. 27, Iss. 9, 2007-01 ,pp. : 591-604

Adis International

Access to resources Recommend Favorite